Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Universal health coverage in oncology is still not a reality, as a recent report shows
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
A study proposes a model that is able to learn broad aspects of cancer–immune interactions from early phase trial data
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
In the period 2024-2026, the technical collaboration between the United Nations agency and the Society plans a series of evidence-based activities to improve global cancer care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.